findings home/archives       contact us       other AHC publications   

July 2006 Issue

RSS feed

UC Leads Study on Male Breast Cancer Drug Combination

By Amanda Harper
Published July 2006

Medical oncologist Zeina Nahleh, MD, wants to know whether a certain drug combination can slow the progression of male breast cancer, a rare disease that often goes undiagnosed until it's in an advanced stage.


Nahleh is leading a national phase-2 clinical trial to test whether the drug anastrozole (Arimidex), currently approved by the Food and Drug Administration (FDA) for treating breast cancer in postmenopausal women, can effectively fight the same disease in men.


”If we’re going to make significant advances against the disease, we need better male-specific treatment strategies,” says Nahleh, director of breast oncology in UC’s division of hematology and oncology.


Previous research has shown that the female hormone estrogen promotes the growth of certain types of breast cancer. Anastrozole is one of a class of drugs, known as non-steroidal aromatase inhibitors, that block the tumor’s use of estrogen and slow its development.


By treating male breast cancer with a combination of anastrozole and a synthetic hormone called goserelin, Nahleh believes she may be able to stop the transition of the male hormone testosterone to the estrogen estradiol, significantly lowering the man’s overall estrogen levels and limiting breast tumor growth.


Goserelin is what is known as a gonadotropin-releasing hormone, which stops testosterone production in men and decreases estradiol in women. It already has FDA approval for the treatment of prostate cancer, endometriosis and advanced premenopausal and perimenopausal breast cancer.


“The biology of breast cancer is different in men and women, so identical treatment methods are not the best solution,” explains Nahleh.


“We believe that anastrozole—when used in conjunction with a gonadotropin-releasing hormone injection—will lower the amount of male estrogen in the body, resulting in better control of the breast tumor.”


The trial, sponsored by the National Cancer Institute’s Southwest Oncology Group, is the first to test this specific drug combination in men with advanced breast cancer.


“We’ve seen a 26 percent increase in the number of male breast cancer cases since 1973, but the disease is so rare that there’s been little research to determine the best ways to detect and treat the disease specifically in men,” explains Nahleh.


Current male breast cancer treatment methods are based on accepted approaches to the disease in women. Unlike female breast cancer, however, says Nahleh, the relationship between the estrogen receptor and overall survival in men is uncertain.


Under Nahleh’s direction, researchers from medical centers nationwide will test the drug combination on about 60 male patients—age 18 or older—who have recurrent or advanced breast cancer.

Patients will receive an anastrozole pill every day and a goserelin injection on the first day of 12, month-long cycles. Every two months researchers will collect serum samples to evaluate blood estrogen levels. They will also obtain CAT scan and X-ray images of the tumor to determine how the patient is responding.


After the treatment, Nahleh and her team will follow patients for three years to determine whether the approach is a sustainable option for managing male breast cancer.


The American Cancer Society estimates that nearly 1,700 men were diagnosed with breast cancer in 2005 and about 27 percent will die from the disease.

 back to list | back to top